Insights
January / February 2018
Modena — Holoclar, the world's first stem cell therapy, was approved by the EMA in 2015 for patients with extreme corneal damage. It is manufactured by Holostem Advanced Therapies, a spinoff of the University of Modena.
Milan — The world's first ex vivo stem cell gene therapy based on Italian research and developed by GlaxoSmithKline in collaboration with Fondazione Telethon and Ospedale San Raffaele. Approved by the EMA in 2016, the treatment is for children with ADA-SCID, a rare disease also known as “bubble baby” disease.
Milan — The San Raffaele Scientific Institute of Milan, research partner to spinoff biotechnology company Gernenta, developing novel gene transfer cancer treatments.
Origgio — BioUpper provides support for innovation in the life sciences, giving startups access to biomedical resources, facilities, and experts. Partners include Novartis and the philanthropic Fondazione Cariplo.
Lazlo — One of the top ten EU regions for number of workers in the pharmaceutical industry and home to Lazio Innova, a cluster of universities, hospitals, IT, and biopharmaceutical companies.
Lombardy — With 46,000 employees, this is another of the EU's top ten regions for pharmaceutical workers. In addition, Italy has a robust program of clinical trials, half of which are conducted in Lombardy.
ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition) outlines how to apply a risk-based approach to GxP computerized systems and is aligned with the FDA draft guidance “Computer...
An ISPE campaign in 2016 piqued my interest in the Women in Pharma committee because I’m an advocate for women in the workplace. When I became President of the ISPE Philippines Affiliate in 2017, I knew that Women in Pharma...
Next year promises to be a busy one for ISPE. The year starts with the 2024 ISPE Facilities of the Future Conference in San Francisco and is quickly followed by the